A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
S1801 is permanently closed to accrual, effective May 5, 2022, at 11:59pm Pacific Time.